Lung Regeneration Pathway

Pathway overview

Public sources describe an autologous lung progenitor or airway basal-cell pathway for selected conditions such as COPD, ILD/IPF and bronchiectasis within a designated clinical application setting. The exact indication, workflow and current intake must be confirmed case by case.

Information likely required for review

• Confirmed respiratory diagnosis
• Recent high-resolution chest CT report and images
• Pulmonary function tests including FEV1, FVC and DLCO where available
• Six-minute walk test or oxygen requirement
• Smoking history
• Current inhaled and systemic medications
• Cancer, infection and major comorbidity history

What happens after submission

1. RMC checks the case summary and missing records.
2. Where a credible route exists, the case is prepared for an appropriate medical institution.
3. The hospital decides whether consultation, further testing or in-person assessment is warranted.
4. A formal plan and fee structure, if applicable, should come after medical review.

Evidence and limitations

Cell and regenerative therapies may have condition-specific evidence, eligibility rules, risks and uncertainties. Results from a study population do not predict an individual outcome. Standard treatment options should also be discussed with a qualified physician.

Public sources used for pathway identification

• Hainan government — frontier biomedical projectsOfficial overview of projects in Boao Lecheng.
• Technology provider — public pipeline updatePublic company information on clinical development and clinical translation/application activity.
• Technology provider — pathway descriptionPublic description of the clinical workflow and treating institution.